NEW
YORK, Oct. 14, 2024 /PRNewswire/ -- Baird
Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or
the "Company"), a leading developer and provider of microwave
ablation ("MWA") medical devices in China, which recently expanded into the U.S.
market following its U.S. FDA 510(k) clearances, today announced
its participation in the upcoming American Thyroid Association
(ATA) Annual Meeting. The event is scheduled to take place from
October 30 to November 3, 2024, at
the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
Baird Medical will showcase its innovations at Booth 100, one of
the largest exhibitor spaces at the event, featuring the Company's
latest advancements in MWA technology and highlighting its impact
on thyroid care. During the event, the Company will also host an
Expo Theater Presentation on November 2,
2024, from 10:25 AM to 11:25
AM, inside the Exhibit Hall of the Chicago Ballroom. The
session, titled "Latest Advancements in MWA for Thyroid Treatment,"
will provide valuable insights into recent developments in this
field. It will feature Dr. Emad
Kandil from Tulane University,
Dr. Feng Than from Sun Yat-sen University, and Dr. Khadra Helmi from Houston Methodist
Hospital.
"We are excited to participate in the ATA Annual Meeting and
present our innovations in microwave ablation technology," said
Haimei Wu, Co-Founder of Baird Medical. "This event is an excellent
opportunity to engage with leading experts and foster meaningful
relationships to advance thyroid care. We warmly invite all
attendees to visit our booth and attend our Expo Theater
Presentation to explore our cutting-edge MWA technology."
Baird Medical's participation in the event underscores its
expansion into the U.S. market, following a successful listing on
the Nasdaq exchange. The Company's recent FDA clearance for its
minimally invasive microwave ablation technology offers a promising
alternative to thyroidectomy for patients with benign thyroid
tumors. With over 150,000 thyroidectomies performed annually in the
U.S., Baird Medical's minimally invasive microwave ablation offers
a safer, less invasive alternative for treating benign thyroid
tumors.
About the ATA® Annual Meeting
The ATA® Annual Meeting is the world's preeminent event for
those interested in thyroid diseases and disorders. It's an
opportunity for peer-to-peer learning and collaboration through
lectures, interactive discussions, meet the professor sessions, and
abstracts.
About Baird Medical
Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading
microwave ablation ("MWA") medical device manufacturer and provider
in China and a recent entrant to
the United States market. Baird
Medical's proprietary devices are used to treat both benign and
malignant tumors, including thyroid nodules, liver cancer, lung
cancer, and breast lumps. Baird Medical is the first company to
obtain a Class III medical devices registration certificate for MWA
medical devices specifically indicated for thyroid nodules in
China. For more information,
please visit http://www.bairdmed.com/.
Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com
Public Relations
Brad Burgess, Senior Vice
President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com
View original
content:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-the-american-thyroid-association-ata-annual-meeting-302275013.html
SOURCE Baird Medical Investment Holdings Ltd.